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What does the arthropathy of alkaptonuria teach
us about disease mechanisms in osteoarthritis and
ageing of joints?
5 Strap line: Lessons from a rare disease
Rare diseases are a neglected area of study in OA. Our
hypothesis is that greater focus on rare cartilage syn-
dromes would lead to more rapid advancement in under-
10 standing OA and age-related joint degeneration. OA is one
of the major causes of disability, yet despite major re-
search efforts, there are no therapies and a limited
number of biomarkers. In extreme phenotypes of
Mendelian disorders, disease progression is often rapid
15 and predictable, so it is easier to identify the initiation
and advance of pathological changes. Careful observation
of extreme phenotypes could help elucidate the patho-
genesis of OA and lead to new biomarkers and thera-
peutic targets. Here we describe how investigating
20 arthropathy in the rare genetic disease alkaptonuria
AQ3 (AKU) has provided important lessons for OA and ageing
of joints.AQ1
The idea that we can learn from rare diseases is not
new. In the Annual Oration to the Medical Society of
25 London in 1928, Sir Archibald Garrod, whose research
on AKU led to the concept of inborn errors of metabolism,
delivered a presentation entitled ‘The Lessons of Rare
Maladies’ [1]. Garrod recalled the teaching of William
Harvey, who, in a letter to John Vlackveld in 1657,
30 observed ‘nor is there any better way to advance the
proper practice of medicine than to give our minds to
the discovery of the usual law of nature, by careful inves-
tigation of cases of rarer forms of disease’ [2].
The words of Garrod and Harvey proved to be pro-
35 phetic, as research on monogenic diseases has helped
elucidate the pathogenesis of common disorders.
Several therapies for common diseases, including the
blockbusters statins and bisphosphonates, were dis-
covered in part through the study of rare syndromes.
40 The investigation of high bone mass phenotypes in scler-
osteosis and Van Buchem’s disease has revealed the role
of Wnt signalling and sclerostin in bone, leading to new
drug targets.
Despite many examples from other fields on the wider
45 benefits of rare disease research, the potential impact of
studying less common cartilage syndromes in OA has
been neglected. Research has been focused on prevailing
trends, including cell signalling, stem cells and genomics,
all important areas of research, but none of which has
50 been particularly productive in elucidating the pathogenic
mechanism or identifying new therapies and biomarkers.
Tissue homeostasis is regulated by many interacting
signalling pathways. Once joint degeneration has been
initiated and there are ultrastructural, anatomical and
55mechanical changes, all pathways will be disrupted.
Research on the secondary downstream consequences
will not reveal the primary pathological mechanism of OA.
The potential for cell therapy with stem cells or chon-
drocytes to repair damaged joints is limited, probably to
60conditions of focal trauma rather than degeneration. OA is
a disease of the whole joint and anatomical changes in the
underlying bone accompany or even precede cartilage
loss. Resurfacing a joint in which the subchondral bone
plate and trabeculae are disrupted is analogous to the
65futile renewal of tiles on an uneven roof in which the
underlying timbers are warped.
Despite the resources pumped into untargeted gen-
omics, the candidate gene with the most impressive OA
association is GDF5, which is a chondrodysplasia gene,
70already known through rare disease research [3]. Similarly,
mutations of ANKH in chondrocalcinosis [4] have high-
lighted the role of pathological mineralization in more
common OA. More than 40% of patients with OA have
detectable mineral deposits in cartilage [5]. These are
75separate examples of how research on rare diseases
other than AKU can contribute to understanding the
pathophysiology of OA.
Our research has focused on AKU, a monogenic defect
in tyrosine metabolism that leads to early onset, aggres-
80sive joint degeneration. Although joint destruction in AKU
is associated with the deposition of pigmented polymers
in cartilage, termed ochronosis, there are parallels with the
pathophysiology of OA. Studies on tissue samples from
AKU patients and from an AKU mouse model have re-
85vealed previously unidentified microanatomical, cellular
and biochemical changes in joints that have been subse-
quently recognized in human OA.
The sequence of pathological changes in AKU and the
parallels in OA are as follows. Age-related changes occur
90in the composition and organization of the extracellular
matrix, including loss of proteoglycans and disruption of
collagen fibrils. These are exacerbated by trauma.
Collagen fibres lacking protective proteoglycans are at-
tacked by reactive molecules. In AKU, homogentisic
95acid is the culprit leading to ochronosis [6], whereas in
non-AKU joints, reaction with sugar molecules lead to
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formation of advanced glycation end-products.
Chemically modified collagen fibres become stiffened
and less resistant to mechanical loading, leading to a
downward spiral of structural damage. In AKU and pos-
5 sibly in OA, this cascade is initiated in calcified cartilage
and spreads throughout the hyaline cartilage to the articu-
lar surface [7]. Increased stiffness of collagen leads to
aberrant transmission of mechanical loading through car-
tilage to underlying bone [7]. The subchondral plate is
10 subjected to direct damage through aberrant loading
and load-induced remodelling. There is focal loss and
focal sclerosis of the subchondral plate [7] and aberrant
remodelling of the underlying bone, including formation of
trabecular excrescences [8]. Of major significance is that
15 microscopic cracks appear in the subchondral plate, lead-
ing to formation of high-density mineralized protrusions
[9]. These abrasive structures contribute to the destruc-
tion of cartilage. Although we initially discovered high-
density mineralized protrusions in the cartilage of a
20 femoral head from a patient with osteoarthopathy of
AKU, we have subsequently found these novel microana-
tomical structures in OA hip and knee joints, indicating
that they are widespread in OA. Their formation consti-
tutes a newly recognized mechanism of joint destruction
25 in AKU and in OA and provides a new imaging biomarker
and a potential target for drug therapy.
These features are easily recognizable in the severe
phenotype of AKU. The analogous changes in OA are
more difficult to detect because they occur at a lower
30 frequency, but they are no less important.
In conclusion, we provide evidence that studying rare
cartilage syndromes can help elucidate the pathophysio-
logical mechanisms involved in joint destruction. Further
support for rare disease research could make a significant
35 contribution to the development of effective therapies and
new biomarkers for OA.
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